


**Figure S1.** Kaplan–Meier analysis of event-free survival (EFS) and overall survival (OS) by RECIST objective response of the primary tumor (**A,B**) and pretreatment TGR0 (**C,D**) in a subgroup of patients treated by neoadjuvant nivolumab-based therapy.  $p$ -values were obtained using the log-rank test.



**Figure S2.** Kaplan–Meier analysis of event-free survival (**A**) and overall survival (**B**) by major pathological response (MPR).  $p$ -values were obtained using the log-rank test. EFS: event-free survival; OS: overall survival..